Various immunotherapeutic agents such as interleukin-2 (IL-2), ipilimumab, nivolumab, or anti-PD-1L demonstrate a long-lasting survival of fraction of patients, which can eventually translate into the cure of metastatic melanoma. Here, IL2 is linked to metastatic melanoma.